2,816 results match your criteria: "Chronic Inflammatory Demyelinating Polyradiculoneuropathy"
Muscle Nerve
November 2024
Department of Neurology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Barcelona, Spain.
Introduction/aims: Somatosensory evoked potentials (SSEPs) are described as a supportive tool to diagnose chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); however, there is a lack of studies determining the effectiveness of SSEPs in monitoring the clinical course of individuals with this condition. The aims of this study are to evaluate the utility of SSEPs in monitoring patients with CIDP and to assess their association with clinical outcomes following immunomodulatory therapy.
Methods: This was a single-center retrospective observational study that included patients who met European Federation of Neurological Societies and Peripheral Nerve Society criteria for CIDP between 2018 and 2023.
Handb Clin Neurol
August 2024
Department of Neuroscience and Sheffield NIHR Neuroscience BRC, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, United Kingdom.
Autologous hematopoietic stem cell transplantation (HSCT) is associated with 5-year treatment-free remissions in approximately 80% of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who failed or were dependent on intravenous immunoglobulin and or plasmapheresis. Autologous HSCT was associated with significant improvement in strength, independent ambulation, quality of life, nerve conduction velocity, and compound muscle action potential amplitude. The results of HSCT are dependent on proper patient selection, i.
View Article and Find Full Text PDFPatients affected by chronic inflammatory demyelinating polyradiculoneuropathy require close follow up due to the neuronal demyelination along with axonal degeneration associated with the disease process, giving the opportunity to the medical team of adequating therapeutics and other medical interventions, according to the evolution of the symptoms, to prevent irreversible axonal degeneration.
View Article and Find Full Text PDFPract Neurol
August 2024
UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
J Neuroimmunol
September 2024
Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China; Centre for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
The objective is to characterize differentially expressed proteins (DEPs) in Guillain-Barré Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) through high-throughput analysis. Sera from 11 healthy controls (HCs), 21 GBS and 19 CIDP patients were subjected to Olink Proteomics Analysis. In the comparison between CIDP and GBS groups, up-regulation of ITM2A and down-regulation of NTF4 were observed.
View Article and Find Full Text PDFNeurology
August 2024
From the Neuromuscular Diseases Unit (E.P.-G., M.C.-Á., L.Q.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; ERN (European Reference Network) EURO-NMD (Neuromuscular Disorders); and Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER) (E.P.-G., L.Q.), Madrid, Spain.
Front Immunol
July 2024
Department of Neurology, Hebei General Hospital, Shijiazhuang, China.
BMC Neurol
July 2024
School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: Severe post-vaccination neurological complications are rare. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune-mediated polyneuropathy affecting the peripheral nerve roots, which is not well described as a post-vaccination side effect. Here, we present a rare complication of vaccination against SARS-CoV-2, reaching a diagnosis of CIDP.
View Article and Find Full Text PDFJ Neurol
September 2024
Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an inflammatory disease affecting the peripheral nerves and the most frequent autoimmune polyneuropathy. Given the lack of established biomarkers or risk factors for the development of CIDP and patients' treatment response, this research effort seeks to identify potential clinical factors that may influence disease progression and overall treatment efficacy.
Methods: In this multicenter, retrospective analysis, we have screened 197 CIDP patients who presented to the University Hospitals in Düsseldorf, Berlin, Cologne, Essen, Magdeburg and Munich between 2018 and 2022.
Eur J Neurol
October 2024
Department of Neurology, Takai Hospital, Nara, Japan.
Eur J Neurol
October 2024
Aston Medical School, Aston University, Birmingham, UK.
Background And Purpose: The amplitude, timing, and determinants of improvement with available treatments are uncertain in chronic inflammatory demyelinating polyneuropathy (CIDP). Our primary objective was to quantify categorized outcomes with routine care.
Methods: We retrospectively studied treatment response within 36 months from initiation in 112 consecutive subjects with CIDP.
Neurol Genet
August 2024
From the Université Paris Cité (A.R., M.S.), Institut Imagine, Génétique des maladies mitochondriales, INSERM UMR 1163; Centre de Référence des Maladies Mitochondriales (A.R., P.G., G.B., Z.A., C.-M.B., M.B., M.-T.A.-W., P.D.L., I.D., E.G., E.J., A.D.S.-M., N.B., A.M., M.S.), AP-HP, Hôpital Necker-Enfants Malades, Paris; Service de Biochimie (P.G.), AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre; Service de médecine génomique des maladies rares (G.B., Z.A.), AP-HP, Hôpital Necker-Enfants Malades, Paris; Service de Génétique (M.B., D.B.), Centre Hospitalier Universitaire; Service de génétique clinique (L.D.), Centre de Compétences Maladies Héréditaires du Métabolisme, CHU de Rennes; Unité de Gastroentérologie (N.L., P.B.), Hépatologie, Nutrition, Diabétologie et Maladies Héréditaires du Métabolisme, Hôpital des Enfants, CHU de Toulouse; Service de Neuropédiatrie (M.-T.A.-W., A.D.S.-M.), CHU de Strasbourg; Service de Neurométabolisme pédiatrique (B.C.), CHU Timone, Marseille; Service et Centre de référence des maladies héréditaires du métabolisme (P.D.L., M.S.); Service de Neurophysiologie pédiatrique (I.D., C.G.), AP-HP, Hôpital Necker-Enfants Malades, Paris; Service de Génétique (A.G.), CHU de Rouen; Pediatric Hepatology and Pediatric Liver Transplant Unit (E.G., E.J.), AP-HP, CHU Bicêtre, Le Kremlin-Bicêtre; Laboratoire de Biochimie et Biologie Moléculaire (P.A.-B.), CHU d'Angers; Pédiatrie générale et maladies infectieuses (V.A.), AP-HP, Hôpital Necker-Enfants Malades, Paris; Service de médecine infantile (C.B.), CHU de Nancy; Service de Réanimation pédiatrique et néonatale (P.D.), AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre; Centre de référence des maladies héréditaires du métabolisme (A.F.), Hospices civils de Lyon, CHU de Lyon; Service de génétique médicale (B.I.), CHU de Nantes; Service de Neurologie Pédiatrique (M.J.), AP-HP, Hôpital Robert Debré, Paris; Génétique Clinique et Oncogénétique (G.J.), CHU Amiens-Picardie; Service de Neurologie pédiatrie (H.M.), AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre; Centre de référence des Maladies Héréditaires du métabolisme (K.M.), Hôpital Jeanne de Flandre, Lille; Service de Génétique Clinique (S.S.O., L.P.), CRMR anomalies du développement CLAD-Ouest, Rennes; Service de neurologie pédiatrique (C.R.-J.), Hospices civils de Lyon, CHU de Lyon; Imagerie pédiatrique (C.-J.R., N.B.), AP-HP, Hôpital Necker-Enfants Malades, Université Paris Cité; and Université Paris Cité (A.M.), Imagine Institute, INSERM UMR 1163, Paris, France.
Muscle Nerve
November 2024
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Introduction/aims: Not all patients with chronic inflammatory demyelinating polyneuropathy (CIDP) have evidence of demyelination on nerve conduction studies (NCS). Patients with "supportive" evidence of CIDP on cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), ultrasound (US), or nerve biopsy but not on NCS, often receive immunomodulating therapy. We evaluated the treatment response of patients with clinical and supportive features of CIDP lacking NCS evidence of demyelination.
View Article and Find Full Text PDFCase Rep Neurol Med
June 2024
Department of Neurology, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho Shinjuku-ku, Tokyo, Japan.
Neurol Sci
November 2024
Faculty of Urban and Regional Planning, Cairo University, Giza, Egypt.
Background: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) presents significant treatment challenges due to its chronic nature, varied clinical presentations, and rarity. Subcutaneous immunoglobulin (SCIG) has emerged as a maintenance therapy, offering potential advantages in administration and patient experience over the previously recognized intravenous immunoglobulin (IVIG).
Methods: We included all clinical studies involving CIDP patients treated with SCIG from eleven databases up to March 2024.
Int J Mycobacteriol
April 2024
Department of Neurology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India.
Fortschr Neurol Psychiatr
June 2024
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic autoimmune disease of the peripheral nervous system. It is often difficult to diagnose, but severaly therapeutic options are nowadays available to reduce neurological deficits and to improve the disease course. This article exemplifies the management of CIDP by a typical case study.
View Article and Find Full Text PDFMedicine (Baltimore)
June 2024
Department of Neurology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China.
J Peripher Nerv Syst
June 2024
Department of Neurology, King's College Hospital, London, UK.
Curr Opin Neurol
October 2024
Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.
Purpose Of Review: There is no diagnostic biomarker that can reliably detect Guillain-Barré syndrome (GBS) or chronic inflammatory demyelinating polyneuropathy (CIDP). Diagnosis relies upon integrating key clinical characteristics and relevant supportive data. Consequently, misdiagnosis and delayed diagnosis are common.
View Article and Find Full Text PDFClin Chem Lab Med
June 2024
131795 Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM , Montpellier, France.
Objectives: Autoimmune nodopathy (AN) is a life-threatening peripheral neuropathy mediated by four autoantibodies targeting axoglial cell adhesion molecules at the nodes of Ranvier: Neurofascin-155 (Nfasc155), PanNeurofascin (PanNfasc), Contactin-1 (CNTN1), and Contactin-associated protein 1 (CASPR1). Antibody detection is a strong biomarker for AN diagnosis and treatment monitoring. The aim of this study was to develop an immuno-dot assay (immuno-DOT) compatible with routine implementation in medical laboratories.
View Article and Find Full Text PDFJ Peripher Nerv Syst
June 2024
Department of Neurology, Takai Hospital, Tenri, Nara, Japan.
HGG Adv
July 2024
Precision Medicine & Computational Biology, Sanofi, Cambridge, MA, USA. Electronic address:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, immune-mediated disorder in which an aberrant immune response causes demyelination and axonal damage of the peripheral nerves. Genetic contribution to CIDP is unclear and no genome-wide association study (GWAS) has been reported so far. In this study, we aimed to identify CIDP-related risk loci, genes, and pathways.
View Article and Find Full Text PDFAutoimmunity
December 2024
Neuromuscular Immunopathology Research Laboratory, Division of Neuromuscular Disease, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Immune-mediated demyelinating polyneuropathies (IMDPs) are rare disorders in which dysregulated adaptive immune responses cause peripheral nerve demyelinating inflammation and axonal injury in susceptible individuals. Despite significant advances in understanding IMDP pathogenesis guided by patient data and representative mammalian models, specific therapies are lacking. Significant knowledge gaps in IMDP pathogenesis still exist, e.
View Article and Find Full Text PDF